KDR and central nervous system cancer: Sunitinib, a small molecule that inhibits VEGF/VEGFR signaling through the selective inhibition of multiple tyrosine kinase receptors such as VEGFR-1,2,3, PGDFR-α, and β is undergoing phase two clinical trials in glioma patients [33].